[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370555-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370555-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","febrasgo-position-statement-follow-up-of-women-after-gynecological-cancer-treatment-number-3-2025","FEBRASGO POSITION STATEMENT - Follow-up of women after gynecological cancer treatment - Number 3 - 2025","","FEBRASGO (Brazilian Federation of Gynecology and Obstetrics Associations) presents a position statement on follow-up care for women after gynecological cancer treatment, grounded in scientific evidence and intended to support clinical practice. It emphasizes the growing population of cancer survivors and the goal of long-term monitoring for early detection of local, nodal, or distant recurrence. The guidance highlights symptom assessment, physical exams, and evidence-informed use of laboratory or imaging tests, with condition-specific recommendations for markers such as CA-125 and tumor-specific cytology and markers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/febrasgo-position-statement-follow-up-of-women-after-gynecological-cancer-treatment-number-3-2025/370555/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/febrasgo-position-statement-follow-up-of-women-after-gynecological-cancer-treatment-number-3-2025/370555.png","ImageObject",300,407,{"name":42,"@type":43},"Alex Sinclair","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of long-term follow-up after gynecological cancer treatment?","Question",{"text":63,"@type":64},"To detect recurrences early, including local, lymph node, or distant metastases.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How should symptom assessment and physical examination be used during follow-up?",{"text":68,"@type":64},"Symptom assessment and physical examination are important components of follow-up for patients treated for gynecological neoplasms.",{"name":70,"@type":61,"acceptedAnswer":71},"Are laboratory or imaging tests recommended for asymptomatic patients?",{"text":72,"@type":64},"Use of laboratory or imaging tests in asymptomatic patients should be based on evidence that improves survival or enables less morbid treatment, while considering cost and availability.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370555,1790318803,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","FEBRASGO POSITION STATEMENT  \nFollow-up of women after gynecological cancer treatment  \nNumber 3 – 2025  \nDOI: [http://dx.doi.org/10.61622/rbgo/2025FPS3](http://dx.doi.org/10.61622/rbgo/2025FPS3)  \nThe National Specialized Commission on Gynecological Oncology of the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO) endorses this document. The production of the content is based on scientific evidence on the proposed theme and the results presented contribute to clinical practice.  \nKey points  \n• The population of female cancer survivors has increased over the last few years, highlighting the importance of appropriate follow-up of these patients.  \n• The main objective of long-term follow-up for patients treated for cancer is the early detection of recurrences, whether local, lymph node or distant metastases.  \n• Symptom assessment and physical examination play an important role in the follow-up of patients treated for gynecological neoplasms.  \n• The use of laboratory or imaging tests to detect recurrence in asymptomatic patients should be based on evidence that it improves survival or provides less morbid treatments, also considering cost and availability.  \nRecommendations  \n• The frequency of follow-up of patients varies according to the neoplasm, stage, treatment and risk of recurrence.  \n• Patients should be advised about signs and symptoms suggestive of recurrence, which vary according to the neoplasm treated.  \n• Imaging tests are indicated in cases of clinical suspicion of recurrence of gynecological neoplasms.  \n• The use of CA-125 is not routinely recommended in the follow-up of endometrial cancer. However, in ovarian neoplasms in which CA-125 was elevated before primary treatment, its use may have prognostic value.  \n• Germ cell tumors of the ovary have specific markers that can be used during follow-up.  \n• Although evidence is limited, cytology can be performed annually in the follow-up of patients treated for neoplasms of the cervix, vulva, and vagina. Prior radiotherapy increases the false-positive rate.  \n• Patients treated with radical surgeries of the vulva and vagina should be monitored by professionals experiencedin the treatment and physical examination of these neoplasms.  \nBackground  \nEach year, gynecological cancers are responsible for approximately 1.5 million new diagnoses and more than 680,000 deaths worldwide.(1) In Brazil, more than 32,000 new cases are expected in 2024.(2) Numerous advances in gynecological oncology over the last few years have increased the survival of these patients, who now consist of a larger and longer-lived population of survivors.(3)  \nBased on the idea that early detection of recurrences can lead to less invasive treatments with a higher survival rate, providing adequate follow-up for these women is essential. Furthermore, it is crucial  \nthat the fear of relapse and anxiety preceding follow-up appointments after treatment do not impact quality of life and use of health services.(4) The costs and availability of resources to perform these tests should also be considered.(5,6) Nevertheless, many studies report that cancer survivors often do not receive appropriate care.(7,8)  \nDespite advances in treatments and increased survival rates for surviving patients, the available information regarding follow-up after treatment for gynecological neoplasms lacks scientific evidence, and is predominantly derived from retrospective studies and expert opinions. (3) Some fol-  \nFEBRASGO POSITION STATEMENT Rev Bras Ginecol Obstet. 2025;47:e-FPS3.  \n1  \nFollow-up of women after gynecological cancer treatment  \nlow-up models currently adopted may be inflexible and do not provide personalized, cost-effective care to patients. (9) Therefore, informing gynecologists about the frequency, assessment, and examinations required for follow-up of lower genital tract cancers is essential to optimize the care provided to these patients.  \nEndometrial cancer  \nEndometrial canc","cbCaibwDheeQHQ6r","https://ap.wps.com/l/cbCaibwDheeQHQ6r","pdf",167765,11,"English","# Key points\n# Recommendations\n# Background\n# Endometrial cancer","[{\"question\":\"What is the main objective of long-term follow-up after gynecological cancer treatment?\",\"answer\":\"To detect recurrences early, including local, lymph node, or distant metastases.\"},{\"question\":\"How should symptom assessment and physical examination be used during follow-up?\",\"answer\":\"Symptom assessment and physical examination are important components of follow-up for patients treated for gynecological neoplasms.\"},{\"question\":\"Are laboratory or imaging tests recommended for asymptomatic patients?\",\"answer\":\"Use of laboratory or imaging tests in asymptomatic patients should be based on evidence that improves survival or enables less morbid treatment, while considering cost and availability.\"}]","FEBRASGO POSITION STATEMENT - Follow-up of women after gynecological cancer treatment - Number 3 - 2025 | PDF",1790189110,28]